Ospedale Di Circolo

Rho 20017

3 studies enrolling now · 4 studies all time

What they study most

Crohn's Disease, Obesity or Overweight, Ulcerative Colitis, Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe

Studies at this site

• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Recruiting now
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Recruiting now
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling